To evaluate the role of C-fibers in the development of cardioprotective effect of remote ischaemic preconditioning (RPc) during myocardial ischaemia and reperfusion. Materials and methods: experiments have been conducted on 80 anaesthetized Wistar male rats (250-350g weight), divided into two experimental protocols. Protocol 1. The protocol included 30 neonatal rats, which were divided into two groups. In the first group (n=15), capsaicin was injected to animals in neonatal period in order to degenerate sensitive C-fibers. When achieved 250g, the rats were subjected to 30 min myocardial ischaemia and 120 min reperfusion (Control-AMI, n=7, Capsaicin-AMI, n=6) or 15-min both femoral arteries occlusion 25 min before coronary artery occlusion (Control-RPc, n=8; Capsaicin-RPc, n=9). Protocol 2. The first group of animals (Control) was subjected to 30-min myocardial ischaemia with following 120-min reperfusion only. In the second and third animal group 15-min bilateral femoral arteries occlusion was performed 25 min before the onset (RPc group) or 25 min after the onset (RPc25' group) of ischaemia. The animals of the fourth and fifth groups capsaicin was injected subcutaneously 25 min before the onset and on the 25 min after the onset of ischaemia (Capsaicin and Capsaicin25'groups). Results: Protocol 1. Infarct size was comparable in Control-AMI and Capsaicin-AMI groups (45±4% and 43±1%) respectively. No infarct size reduction was observed in Capsaicin-RPc group compared to Capsaicin-AMI group (p>0,05). Protocol 2. Significant reduction in infarct size was observed in groups, where femoral arteries occlusion was performed 25 min before the onset and on the 25th min after the onset of ischaemia, as well as in those, where capsaicin was injected before myocardial ischaemia, comparing to control group (p<0,001). There was no infarct-size reduction if capsaicin was injected on the 25th min of ischaemia (p>0,05 vs. Control). Conclusions: the results suggest that activation of С-fiber afferents by topical application of capsaicin to the peripheral tissue prior to myocardial ischaemia/reperfusion limits myocardial injury, mimicking the effect of remote preconditioning, but it doesn't play a key role in the development of RPc applied 25 min after the onset of ischaemia.

Main purpose of our study was to examine the comparative effects of enalapril and losartan on the performance of daily blood pressure monitoring at the patients with hypertension. 100 patients with II stage hypertension participated in this study. Age of patients ranged from 35 to 80 years (32 male; 68 female). Daily monitoring was carried out using 24- hour pressure monitor (CBM-01) serial number 201 001 by standard methods. 50 patients used ACE inhibitor enalapril maleate (KRKA, Sloveniya) in a dose of 5-20 mg / day for 12 weeks. 50 patients received losartan (MRKTD by Brown London) 25-50 mg / day. Received data were statistically processed by methods of medical statistics due to all modern standards. As enalapril, and losartan alone showed an adequate corrective efficacy in the morning of the absolute values of the blood pressure dynamics, «pressure load» indicators, but in a comparative analysis did not reach statistical significance. Each of the drugs showed us an adequate corrective efficacy of the absolute values at the morning blood pressure dynamics, but comparative analysis of statistical significance was not observed. Comparing to Losartan, Enalapril statistics were much better, while average nocturnal blood pressure were better decreased by losartan. In addition, it should be noted that despite the identical effect of the drugs, losartan is better tolerated than enalapril, without any side effects.

In order to study left ventricular (LV), inter/- and intraventricular asynchrony, LV diastolic function in myocardial infarction (Ml), we examined 58 patients with primary anterior - septal infarction without signs of heart failure (HF) with left ventricular ejection fraction (EF), left ventricular more than 40%. The patients were divided into 2 groups: group 1 - patients with myocardial infarction with normal -sized left ventricle (DLC LV <5,5 cm) (n = 28), group 2 - patients with myocardial infarction with left ventricular dilatation (RIC LV 5,6-6,0 cm) (n = 30).The results showed that patients with, asymptomatic dilation of left ventricular are more pronounced maladaptive LV remodeling processes and inter/ - intraventricular asynchrony, and as noted more severe diastolic dysfunction (DD) of the left ventricle.

Acute coronary syndrome and myocardial infarction in one of the Tashkent's districts. Materials and methods: As a base for the present research were used results of cohort prospective research, named «The Register of acute coronary syndrome and myocardial infarction». AIM/ACE was studied in one ofTashkent's districts. Results: from the moment of the research beginning were registered 310 patients with a acute coronary syndrome and myocardial infarction including men-197, women-113. Results of research have shown the greatest prevalence AIM/ACE in age group of 65-69 years and frequency AMI/ACE at men was in 2 times higher than at women: 63,9 % against 36,1 %. The analysis on each of the allocated risk factors has shown that an arterial hypertension (AH) suffered 78,37 % of patients (73,3 % of men and 87,5 % of women), and the analysis on degrees AH has shown that at 12.9 % of patients has second degree of АН, at 4,6 % has third degree of АН. In our research at 75,8 % of patients has overweight and /or obesity, and was observed with identical frequency among men and women (drawing 7). You can see, that age group of 46-49 years at men (82 %) and 55-59 age at women (93 %) occurrence of the given risk factor (obesity of 1-2 degrees) was the greatest. So, research has shown the greatest prevalence AMI/ACS in age group of 65-69 years. The potential of major factors of risk among men and women with AMI/ACS had the features: overweight most often met in age groups of 45-49 years and 55-59 accordingly at men and women.

Aim: investigate the possible influence of fluvastatin on erythrocyte aggregation in hypertensive patients with dyslipidemia. Material and methods: under a supervision there were 32 patients by arterial high blood pressure 1-2 degrees, risk 3 (criteria of DAG3 (2008) with dyslipidemia II6 of type), middle age. A control group was made by 26 healthy people of analogical age. All patients received fluvastatin 40 mg at night on a background of enalapril 10 mg 2 times a day. The estimation of clinical and laboratory indexes was conducted at the beginning of treatment, through 4, 12 and 52 weeks of therapy. Statistical treatment of results was conducted t - Student criterion. Results: in hypertensive patients with dyslipidemia in the damage of blood lipid spectrum, lipid composition of erythrocyte membranes and activation of these lipid peroxidation observed increased aggregation. The use of fluvastatin in hypertensive patients with dyslipidemia over 52 weeks of optimized lipid composition, level of lipid peroxidation of plasma and red blood cells, without bringing these figures to the level of control. Appointment of fluvastatin persons suffering from hypertension with dyslipidemia, reduced the ability of red blood cells to aggregate, not allowing her to achieve a full normalization within a year of therapy.

The aim of the study: to assess the impact of differentiated lipid-lowering therapy on lipid metabolism, immune and inflammatory changes in women with stable angina in menopause. Materials and methods: examined 97 women with stable angina functional class II at menopause (average age 53,6±4,24 years) using instrumental methods (ECG, EKTG-60, Holter ECG monitoring, loading test, coronary angiography) and laboratory (determined by hormonal status, fibrinogen level and hsSRB, lipid profile and blood products LPO). Depending on the identified changes of lipid metabolism prescribed lipid-lowering drugs: atorvastatin, ciprofibrat, combination atorvastatin with antisklerol. Results: after a course of differentiated lipid-lowering therapy in all treatment groups achieved target levels of lipid metabolism. However, in patients receiving atorvastatin significantly decreased the concentration of LPO products (p=0,039) and large molecular 3,5% immune complexes (IC), p=0,041 in early postmenopausal women, of low-molecular 7% IC (p=0,014) in the perimenopause, as well as decreased levels of antibodies to LDL in the late postmenopausal (p<0,01), indicating that the antioxidant and immunomodulatory activity of statins and suggests its function during exacerbation of atherosclerosis in menopausal women. Ciprofibrat treatment led to a reduction of

Clinically manifested chronic heart failure (CHF) is associated with significant decrease of patients' qualityoflife(QL)caused by their functional capability as well as their psychoemotional discomfort. Most informative predictors of QL in CHF are its ischemic origin, age, female sex, NYHA functional class (FC), tachycardia at rest, creatinine clearance, Hb, uric acid and plasma cholesterol levels, moderate-to-severe depression. Data of Minnesota Heart Failure Life Quality/SF-36 questionnaires demonstrate high prognostic value in regard of 1 - 5 year survival in CHF patients with the same NYHA class and so may be useful in risk stratification of patients with comparable functional status.

Aim of the study: to analyze the challenges in management of personal cardiovascular risk in Georgian population. Methods: survey of quantitative and qualitative studies of cardiovascular diseases and risk factors in Georgia. Results: • Failure of screening activities in field of cardiovascular diseases • Failure of epidemiological data regarding cardiovascular diseases in female as well as in male subpopulations • Underestimation of lipid profile abnormalities as priority risk factors by patients as well as by physicians.

The international PH Forum sponsored by Actelion Pharmaceuticals Ltd was held on 11-13 May 2012 in Dublin, Ireland. A broad range of topics were covered by PH experts, most notably Nazzareno Galie, Lewis Rubin and Gerald Simonneau.